Source:http://linkedlifedata.com/resource/pubmed/id/16253380
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2006-3-28
|
pubmed:abstractText |
We studied the efficacy of four different treatment regimens (sulphonylurea and metformin+/-acarbose versus glimepiride and rosiglitazone versus glimepiride and bedtime NPH insulin versus multiple actrapid and NPH insulin injections) in poorly controlled type 2 diabetes subjects on hs-CRP, VCAM-1 and AGE at 4, 8 and 12 weeks of treatment. Multiple insulin injections rapidly improved HbA(1c) by 0.6+/-0.9% (p<0.005), 1.2+/-1.3% (p<0.0005) and 1.3+/-1.4% (p<0.0005) at week 4, at week 8 and week 12, respectively. Subjects who continued their existing combination treatment of sulphonylurea, metformin+/-acarbose also showed a significant reduction in HbA(1c) (p<0.05). Although effective in reducing glycemic parameters, there was no reduction in CRP levels in either treatment group. The treatment regimen consisting of rosiglitazone and glimepiride significantly lowered hs-CRP by -2.6 (3.9) mg/L (p<0.05) at week 12 in spite of no improvement in blood glucose. AGE improved in all groups irrespective of type of treatment, glycaemic control and CRP levels. Our data indicate rapid glycaemic control alone does not necessarily result in improvement in markers of inflammation in type 2 diabetes patients.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Blood Glucose,
http://linkedlifedata.com/resource/pubmed/chemical/C-Reactive Protein,
http://linkedlifedata.com/resource/pubmed/chemical/Fructosamine,
http://linkedlifedata.com/resource/pubmed/chemical/Glycosylation End Products, Advanced,
http://linkedlifedata.com/resource/pubmed/chemical/Hemoglobin A, Glycosylated,
http://linkedlifedata.com/resource/pubmed/chemical/Hypoglycemic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Insulin
|
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
0168-8227
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
72
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
48-52
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:16253380-Administration, Oral,
pubmed-meshheading:16253380-Adult,
pubmed-meshheading:16253380-Analysis of Variance,
pubmed-meshheading:16253380-Blood Glucose,
pubmed-meshheading:16253380-C-Reactive Protein,
pubmed-meshheading:16253380-Diabetes Mellitus, Type 2,
pubmed-meshheading:16253380-Female,
pubmed-meshheading:16253380-Fructosamine,
pubmed-meshheading:16253380-Glycosylation End Products, Advanced,
pubmed-meshheading:16253380-Hemoglobin A, Glycosylated,
pubmed-meshheading:16253380-Humans,
pubmed-meshheading:16253380-Hypoglycemic Agents,
pubmed-meshheading:16253380-Insulin,
pubmed-meshheading:16253380-Male,
pubmed-meshheading:16253380-Middle Aged
|
pubmed:year |
2006
|
pubmed:articleTitle |
Improvement in C-reactive protein and advanced glycosylation end-products in poorly controlled diabetics is independent of glucose control.
|
pubmed:affiliation |
Department of Medicine, National University of Malaysia, Jalan Yaacob Latif, Cheras, Kuala Lumpur 56000, Malaysia. shmdisa@yahoo.co.uk
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|